Fibromyalgia is a complex disease that is difficult to treat because of patient heterogeneity, frequent comorbid conditions, and numerous symptoms, including pain, depression, fatigue, and sleep dysfunction. The few drugs that are FDA-approved for fibromyalgia (i.e., Pfizer’s Lyrica,  Allergan’s Savella, duloxetine [Eli Lilly’s Cymbalta, generics]) have limited efficacy, resulting in off-label use of various antidepressants, analgesics, muscle relaxants, and sleep aids to manage patient symptoms. Although the recognition, diagnosis, and treatment of fibromyalgia have improved dramatically over the past decade, the treatment journeys of fibromyalgia patients remain very complex and include high rates of treatment discontinuation, drug switching, and polypharmacy.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed fibromyalgia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed fibromyalgia patients?
  • How are therapies approved to treat fibromyalgia (Lyrica, Savella, duloxetine) integrated into the treatment algorithm? What are their sources of business?
  • What percentage of fibromyalgia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of fibromyalgia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Allergan, Pfizer

Key drugs: Lyrica, Lyrica CR, Savella, duloxetine, gabapentin, SNRIs, SSRIs, muscle relaxants, NSAIDs, opioid analgesics, sedative hypnotics, and others

Key analysis provided:

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

Table of contents

  • Chronic Pain - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis In Fibromyalgia (US)

Author(s): Audreza Das, P.G. Dip.

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group

She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her B.E. degree in Biotechnology from Birla Institute of Technology, a deemed university and her P.G. Diploma in Cancer Immunology & Biotechnology from University of Nottingham.

Related Reports

Rheumatoid Arthritic Pain - Epidemiology - Mature Markets

DRG Epidemiology's coverage of rheumatoid arthritic pain comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France...

View Details

Chronic Pain - Landscape & Forecast - Disease Landscape & Forecast

A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several drug...

View Details

Chronic Pain - Unmet Need - Detailed, Expanded Analysis: Complex Regional Pain Syndrome (US/FR/DEU/UK)

Complex regional pain syndrome (CRPS) is a debilitating pain condition characterized by persistent pain, typically in distal limbs, with intensit...

View Details

Chronic Pain - Unmet Need - Detailed, Expanded Analysis - Chronic Low Back Pain (US/EU)

Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, represents the largest segment of the chronic pain th...

View Details